Janssen Pharmaceutica N.V.
Turnhoutseweg 30
Beerse
Antwerpen
2340
Tel: 32-14602226
94 articles about Janssen Pharmaceutica N.V.
-
Predicine Announces Collaboration with Janssen to Develop PredicineCARE™ as a Companion Diagnostic Assay in Localized Bladder Cancer
1/8/2024
Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.
-
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
12/26/2023
NANOBIOTIX announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio’s exclusive rights to develop and commercialize potential first-in-class radioenhancer NBTXR3 in China, South Korea, Singapore, and Thailand.
-
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
12/26/2023
LianBio announced that the company has entered into an agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio’s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand.
-
Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration
4/25/2023
Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V.
-
Pipeline Therapeutics Announces Global License and Development Agreement for Investigational Neuroscience Therapy, PIPE-307
4/17/2023
Pipeline Therapeutics announced today that it has entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical.
-
Essential Pharma Announces the Acquisition of HALDOL®
12/7/2022
Essential Pharma announces that it has completed the acquisition of HALDOL® and HALDOL® Decanoate from Janssen Pharmaceutica NV.
-
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
12/5/2022
Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV.
-
Evotec Enters a Drug Discovery Collaboration with Janssen
6/14/2022
Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
4/19/2022
Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.
-
VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen
4/13/2022
VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen’).
-
Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
4/5/2022
Saladax Biomedical, Inc. is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV.
-
Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.
-
Midatech Pharma PLC Announces R&D Collaboration with Janssen on Second Molecule
3/9/2022
Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce an extension of its existing R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.
-
Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing
2/17/2022
Remix Therapeutics today announced a strategic collaboration with Janssen Pharmaceutica NV for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
-
The strategic collaboration centers on Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
-
Midatech Pharma PLC Announces Extension of Janssen collaboration re Q-Sphera
1/17/2022
Midatech Pharma PLC is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020.
-
TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation
1/6/2022
TRexBio Inc. today announced that it has entered into a multi-year research collaboration and licensing agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
SRI International Announces Collaboration Agreement with Janssen
1/5/2022
SRI International (SRI) today announced the company has entered into a collaboration agreement with Janssen Pharmaceutica NV (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica
11/8/2021
Alkermes plc announced that it received notices of partial termination in respect of two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology.
-
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
3/29/2021
Up to 400 million doses of the Company's single-shot vaccine candidate will be made available to African Union member states